8/5/2020 4:04:25 PM
Arena Q2 Loss/Shr $$1.61 Vs Loss $1.24 Last Year
6/15/2020 8:34:01 AM
Arena Pharma Appoints Biotech Executive Katharine Knobil To Board
6/8/2020 4:36:04 PM
Arena Pharma Appoints Chris Cabell As EVP, Head Of Research And Development, And Chief Medical Officer
PR Newswire
6/1/2020 4:02:24 PM
Arena Pharma Announces Completion Of Public Offering Of Common Stock
5/28/2020 8:33:20 AM
Arena Pharma Reports Pricing Of Public Offering Of 5.5 Mln Shares At $50/Shr
5/27/2020 4:03:12 PM
Arena Pharmaceuticals Announces Proposed Public Offering Of Common Stock
5/26/2020 8:32:12 AM
Arena Completes Full Enrollment Of Etrasimod Phase 2 ADVISE Trial Evaluating Etrasimod For Atopic Dermatitis
5/7/2020 4:07:44 PM
Arena Pharma Q1 Loss/share $2.00 Vs. Profit $12.10 Year Ago
4/24/2020 9:03:10 AM
Arena Grants Inducement Stock Options To Certain New Employees
2/26/2020 4:03:23 PM
Arena Pharma Q4 Loss/share $1.76 Vs. Profit $1.35 Year Ago
1/16/2020 9:03:13 AM
FDA Grants Fast Track Designation To Arena' APD418 For Development In Decompensated Heart Failure Patients
1/13/2020 4:10:48 PM
Arena Pharmaceuticals Appoints Joan Schmidt As EVP, General Counsel And Secretary
1/2/2020 8:32:36 AM
Arena Pharma And Beacon Discovery Expand Partnership To Focus On Multiple Immune And Inflammatory Targets